Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors

University of Michigan Rogel Cancer Center (Other)
Overall Status
Recruiting ID
Breast Cancer Research Foundation (Other)

Study Details

Study Description

Brief Summary

This clinical trial will evaluate the adherence, usefulness, satisfaction and effect size for the Sleep Coach app as an intervention for insomnia in 30 adult post-treatment cancer survivors.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Sleep Coach App

Detailed Description

Difficulty sleeping, falling and/or staying asleep, is common in people after they have been diagnosed and treated for cancer. Cognitive Behavioral Therapy for Insomnia (CBT-I) is considered to be the preferred treatment but until now, there has been limited access for most people to CBT-I because it has required an in-person visit with a trained therapist. This research study is to test a mobile CBT-I app called MI Sleep Coach to deliver CBT-I. The goal of this study is to understand if people are willing to use the app, if they find it useful in helping with sleep difficulty and if they are satisfied with using it. The investigators hope to use information from this small feasibility study to study the effectiveness of the app in a larger group of cancer survivors and ultimately to help cancer survivors with sleep difficulties to sleep better.

Study Design

Study Type:
Anticipated Enrollment :
30 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors
Actual Study Start Date :
May 12, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: MI Sleep Coach Mobile Application

The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.

Behavioral: Sleep Coach App
Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
Other Names:
  • MI Sleep Coach
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage of participants engaging with the app at least 4 days/week [7 weeks]

      Adherence will be evaluated using data gathered from the application. Participants will be asked to interact daily with the application and will be deemed adherent if they interact with the app at least 4 times per week for the duration (7 weeks) of the study. Adherence rate will be the number of participants deemed adherent / total number of participants.

    2. Percentage of participants that find the intervention useful [7 weeks]

      Usefulness will be assessed using a survey developed by the investigators of this study called the User Experience Survey, which is based upon the Unified Theory of Acceptance and Use of Technology (UTAUT). The survey assesses perceived ease of use and usefulness of the Sleep Coach app as well as participant satisfaction with the app. To assess usefulness, participants are asked to rate the usefulness of 10 different features of the Sleep Coach app on a scale of 1 to 4, with higher scores indicating greater usefulness. Participants who rate at least one app feature 2 or greater will be considered as finding the intervention useful.

    3. Percentage of participants satisfied with the intervention [7 weeks]

      Satisfaction will be assessed using 2 questions from the User Experience Survey: one to determine the level of overall satisfaction with the app and the other to determine the level of willingness to recommend the app to others. Satisfaction questions are rated on a scale of 1 to 5, with higher scores indicating greater agreement/satisfaction. Participants who rate both questions 4 or greater will be considered satisfied with the Sleep Coach app.

    Secondary Outcome Measures

    1. Effect size of the intervention as measured by the Insomnia Severity Index (ISI). [baseline to 7 weeks]

      The ISI is a 7-item questionnaire used to measure a patient's perceptions of the nature, impact and severity of insomnia. Items are scored on a scale of 0 to 4, with higher scores indicating more severe insomnia. Cohen's d or f will be calculated from baseline to week 7 to assess the effect size of the intervention.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • 18 years of age or older

    • Has completed curative-intent treatment (chemo, surgery, RT) for prostate, colon or breast cancer at least three months and not more than 5 years prior to study entry. Note: Ongoing hormonal therapy (i.e., tamoxifen, aromatase inhibitors, casodex), Herceptin and maintenance therapies are allowed.

    • Ability to read and write English

    • Ability to complete questionnaire(s) by themselves or with assistance.

    • Reports trouble falling asleep or staying asleep on at least 3 nights per week (most weeks) for the last 3 months.

    • Own an Android phone version 8 or higher (The latest version of Android is 11.0) or an iPhone running iOS 11 or higher (The latest version of iOS is 14.3.)

    • Ability to provide informed written consent.

    Exclusion Criteria:
    • Inability to read and write English

    • Diagnosis of a sleep disorder other than insomnia (e.g. sleep apnea, restless legs syndrome, narcolepsy)

    • Diagnosis of Insomnia prior to cancer diagnosis

    • Reports physical symptoms that interfere with sleep, such as shortness of breath, pain, hot flashes, frequent urination

    • Major psychiatric or medical condition other than cancer suspected to contribute to their sleep disturbance

    • Evidence of active cancer (i.e. not considered NED)

    • Currently or previously received CBT-I

    • Patients who are night shift workers or subject to other external restrictions on their opportunity to sleep at night.

    Contacts and Locations


    Site City State Country Postal Code
    1 University of Michigan Rogel Cancer Center Ann Arbor Michigan United States 48109

    Sponsors and Collaborators

    • University of Michigan Rogel Cancer Center
    • Breast Cancer Research Foundation


    • Principal Investigator: Noel Arring, DNP, PhD, RN, University of Michigan

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    University of Michigan Rogel Cancer Center Identifier:
    Other Study ID Numbers:
    • UMCC 2021.004
    • HUM00194610
    First Posted:
    Apr 1, 2021
    Last Update Posted:
    Mar 31, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by University of Michigan Rogel Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2022